CN105832603A - 桂花提取物的制备方法及应用 - Google Patents
桂花提取物的制备方法及应用 Download PDFInfo
- Publication number
- CN105832603A CN105832603A CN201610255932.XA CN201610255932A CN105832603A CN 105832603 A CN105832603 A CN 105832603A CN 201610255932 A CN201610255932 A CN 201610255932A CN 105832603 A CN105832603 A CN 105832603A
- Authority
- CN
- China
- Prior art keywords
- extract
- flos osmanthi
- osmanthi fragrantis
- sweet
- scented osmanthus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 93
- 241000333181 Osmanthus Species 0.000 title claims abstract description 26
- 235000019082 Osmanthus Nutrition 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 22
- 239000002904 solvent Substances 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 235000013305 food Nutrition 0.000 claims abstract description 9
- 239000002537 cosmetic Substances 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 6
- 238000000746 purification Methods 0.000 claims abstract description 5
- 238000001035 drying Methods 0.000 claims abstract description 4
- 238000003756 stirring Methods 0.000 claims abstract description 4
- 241000628997 Flos Species 0.000 claims description 99
- 230000000694 effects Effects 0.000 claims description 25
- 238000000605 extraction Methods 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 9
- 239000012528 membrane Substances 0.000 claims description 9
- 239000000919 ceramic Substances 0.000 claims description 8
- 239000012535 impurity Substances 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 4
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 230000000474 nursing effect Effects 0.000 claims description 3
- 238000001223 reverse osmosis Methods 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000008719 thickening Effects 0.000 claims 1
- 239000000047 product Substances 0.000 abstract description 21
- 230000036541 health Effects 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 4
- 239000000706 filtrate Substances 0.000 abstract 2
- 238000005282 brightening Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 28
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 20
- 108010050345 Microphthalmia-Associated Transcription Factor Proteins 0.000 description 16
- 102000013760 Microphthalmia-Associated Transcription Factor Human genes 0.000 description 15
- 210000004881 tumor cell Anatomy 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 10
- QFRYQWYZSQDFOS-UHFFFAOYSA-N verbascoside Natural products CC1OC(COC2C(O)C(COC3OC(C(O)C(O)C3O)C(=O)O)OC(Oc4cc(O)cc5OC(=CC(=O)c45)c6ccc(O)c(O)c6)C2O)C(O)C(O)C1O QFRYQWYZSQDFOS-UHFFFAOYSA-N 0.000 description 10
- 102000003425 Tyrosinase Human genes 0.000 description 9
- 108060008724 Tyrosinase Proteins 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 241000700199 Cavia porcellus Species 0.000 description 8
- KDSWDGKIENPKLB-QJDQKFITSA-N verbascoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)CCC=2C=C(O)C(O)=CC=2)[C@@H](CO)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O KDSWDGKIENPKLB-QJDQKFITSA-N 0.000 description 8
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 206010040829 Skin discolouration Diseases 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 210000002752 melanocyte Anatomy 0.000 description 5
- 239000012466 permeate Substances 0.000 description 5
- 150000008442 polyphenolic compounds Chemical class 0.000 description 5
- 235000013824 polyphenols Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 244000242564 Osmanthus fragrans Species 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000036564 melanin content Effects 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000006481 glucose medium Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 2
- -1 Alcohol glycoside Chemical class 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 108010039627 Aprotinin Proteins 0.000 description 2
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- JUUBCHWRXWPFFH-UHFFFAOYSA-N Hydroxytyrosol Chemical compound OCCC1=CC=C(O)C(O)=C1 JUUBCHWRXWPFFH-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 2
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- 241000207834 Oleaceae Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 235000019083 Osmanthus fragrans Nutrition 0.000 description 2
- 235000008558 Osmanthus fragrans var thunbergii Nutrition 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 229960004405 aprotinin Drugs 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 210000004694 pigment cell Anatomy 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-Phenylethanol Natural products OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 244000235603 Acacia catechu Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 235000006226 Areca catechu Nutrition 0.000 description 1
- 244000293323 Cosmos caudatus Species 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 101100238555 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) msbA gene Proteins 0.000 description 1
- 101000773083 Homo sapiens 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- 101000796203 Homo sapiens L-dopachrome tautomerase Proteins 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 1
- 101710200814 Melanotropin alpha Proteins 0.000 description 1
- 241000276489 Merlangius merlangus Species 0.000 description 1
- 208000009795 Microphthalmos Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000405911 Rehmannia glutinosa Species 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000007230 Sorghum bicolor Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical group C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229930185474 acteoside Natural products 0.000 description 1
- FBSKJMQYURKNSU-ZLSOWSIRSA-N acteoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O FBSKJMQYURKNSU-ZLSOWSIRSA-N 0.000 description 1
- FBSKJMQYURKNSU-UKQWSTALSA-N acteoside I Natural products C[C@@H]1O[C@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)C=Cc4ccc(O)c(O)c4)[C@H](O)[C@H](O)[C@H]1O FBSKJMQYURKNSU-UKQWSTALSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000037884 allergic airway inflammation Diseases 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000003845 household chemical Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000002796 luminescence method Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 201000010478 microphthalmia Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- KRTSDMXIXPKRQR-AATRIKPKSA-N monocrotophos Chemical compound CNC(=O)\C=C(/C)OP(=O)(OC)OC KRTSDMXIXPKRQR-AATRIKPKSA-N 0.000 description 1
- NCYVXEGFNDZQCU-UHFFFAOYSA-N nikethamide Chemical compound CCN(CC)C(=O)C1=CC=CN=C1 NCYVXEGFNDZQCU-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 238000005220 pharmaceutical analysis Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 1
- SFVVQRJOGUKCEG-OPQSFPLASA-N β-MSH Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-OPQSFPLASA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
Abstract
本发明公开了一种桂花提取物的制备方法,步骤包括:1)选取干桂花为原料,进行粉碎;2)加入步骤1)所得原料质量的5‑20倍的溶剂,在25‑95℃下,搅拌提取桂花提取液30‑180分钟,过滤;3)将步骤2)所得桂花提取液离心,纯化,收集滤过液;4)将滤过液浓缩至浸膏比重为1.10‑1.30,得到桂花提取浸膏;5)对所述桂花提取浸膏进行干燥,得到桂花提取物。本发明还公开了该桂花提取物的用途。本发明通过改进桂花提取工艺,不仅简化了工艺,降低了成本,而且提取出的桂花提取物可以作为天然亮肤原料,安全地用于食品、药品、保健品、护理品、化妆品领域。
Description
技术领域
本发明涉及日用化学领域,特别是涉及一种桂花提取物的制备方法及其在制备亮肤与改善肤色产品中的应用。
背景技术
人体皮肤的颜色由皮肤最外层,即表皮中的黑色素细胞以及其产生的黑色素水平所决定。日光中的紫外线照射是黑色素合成增加的主要诱因,同时黑色素合成也受到促黑素(MSH)、小眼畸形相关转录因子(MITF)的调控。(李承新,王玲,皮肤色素沉着发生机制研究进展[J].中国美容医学,2009,09:1372-1375)
在黑色素合成中起调节作用的信号通路有三条,而所有的通路均和小眼畸形相关转录因子(MITF)相关。MITF是基于螺旋-环-螺旋亮氨酸拉链结构的转录因子,它参与了多种细胞包括色素细胞、肥大细胞、破骨细胞的发育、分化和功能调节,其中尤其在色素细胞中起到关键作用。MITF能够调节黑色素细胞的分化以及黑色素生成酶(酪氨酸酶、酪氨酸酶相关蛋白1(TRP-l)、酪氨酸酶相关蛋白-2(TRP-2))和黑素小体结构蛋白的转录。MITF通过与酪氨酸酶、TYRP1和TYRP2基因中启动因子区M box结合,反式激活这些目的基因表达。(Jody P.Ebanks,R.Randall Wickett,Raymond E.Boissy.Mechanisms Regulating Skin Pigmentation:The Rise and Fall of Complexion Coloration.Int.J.Mol.Sci.2009,10,4066-4087.)因此,MITF表达的上调可直接激活黑色素合成相关酶的表达,从而刺激黑色素合成。相反,如果MITF表达得到下调可抑制相关酶的表达,从而抑制黑色素合成。
桂花(Osmanthus fragrans(Thunb.)Lour),属木犀科(Oleaceae)木犀属(Osmanthus),又名木樨、岩桂、九里香,品种主要有金桂、银桂、丹桂和四季桂四大品种,是中国传统十大名花之一。桂花在中国已有2500多年的栽培历史,作为景观植物外,还具有较高的食用和药用价值,被广泛应用于食品、化妆品及药品中。过去关于桂花中化学成分的研究多集中在对其精油香气成分的分析,近几年随着对桂花的研究深入,桂花中多酚类物质受到越来越多的关注。
Chien-Ya Hung等(2012)在研究桂花多酚的抗氧化功效时,从桂花追踪分离得到毛蕊花糖苷等多酚成分;丁立新等(2013)运用高效液相方法对于不同产地的桂花分析发现,在不同产地桂花中含有丰富的毛蕊花糖苷和红景天苷;Jiang Liu等(2015)对桂花的进一步研究,从桂花中分离得到16种化学成分,大部分为多酚类物质,包括异毛蕊花糖苷、香豆酸等。
基于桂花含有丰富的化学成分,对桂花的加工与提取在很大程度已经产业化,中国是世界上唯一生产桂花浸膏的国家。但是正如公开号为CN 103815213 A的中国发明专利申请中所提到的,目前国内桂花浸膏的生产主要采用传统的石油醚等有机溶剂进行提取,这种方法得率低,所制备产品由于脱醚工艺无法完全脱醚,产品品质达不到食用级标准。尽管该公开号为CN 103815213 A的发明专利申请采用CO2超临界萃取方式制得了食品级桂花提取物,但是该提取设备昂贵,投入成本高,且得率并未有明显提高。
公开号为CN 103767975 A和CN 103768151 A的中国发明专利申请以毛蕊花糖苷等苯乙醇苷类成分作为指标,提出了一种桂花苯乙醇苷提取物的制备方法并对其在美白化妆品中的应用进行了阐述,但是其提取物运用乙醇水为溶剂,并加入了抗氧化剂,调节酸性环境下进行的提取物,后过吸附树脂进行富集制得的较高含量桂花提取物,但是该提取物因为经过乙醇提取和大孔吸附树脂吸附,因此对于乙醇残留、大孔吸附填料中苯乙烯类残留需要进行严格限控,这样就给其在食品以及在保健品中的应用增加了风险。
现代药理研究多报道桂花提取物具有抗氧化和抗炎功效(Hung CY,Huang FL,Shi LS,etal.The Ethanol Extract of Osmanthusfragrans Flowers Reduces Oxidative Stress andAllergic Airway Inflammation in an Animal Model.Evid Based Complement Alternat Med.2013;2013:304290.)。古籍《本草纲目》中记载桂花同百药煎、孩儿茶作膏饼噙,生津辟臭化痰,治风虫牙痛。同麻油蒸熟,润发,及作面脂。《黄帝内经》中记载“肺者,气之本,其华在毛,其充在皮。肺主皮毛。心者,生之本,其华在面,其充在血脉。心主血脉。”桂花暖胃散瘀,温肺生津,有助于润肺、排毒,能改善面部微循环,从内清除肌肤表面的老废角质,达到气血通畅,润肌提亮的作用。桂花功效成分为植物多酚,其中毛蕊花糖苷含量为36.66-71.65mg/g。(丁立新,李焕,范宝俭.HPLC法测定不同产地桂花中红景天苷和毛蕊花糖苷的含量.药物分析杂志.2013,33(5):894-897.)。有文献报道,来源于地黄(Rehmanniaglutinosa)的毛蕊花糖苷作用于B16F10小鼠黑色素瘤细胞,通过激活细胞外信号调节激酶ERK通路下调MITF表达进而抑制酪氨酸酶转录及活性,具有抑制黑色素合成的作用。(Son YO,Lee SA,Kim SS,et al.Acteoside inhibits melanogenesis in B16F10cellsthrough ERK activation and tyrosinase down-regulation.J Pharm Pharmacol.2011Oct;63(10):1309-19.)但未有桂花提取物此类机制报道。
公开号为CN103815284A、名称为“一种女性美容面条及其制备方法”的中国发明专利申请,公开了一种美白面条,其中包含面粉、高粱、绿豆、珍珠、山芋、桂花、芝麻等成分,制得的面条,宣称具有美白去斑功效还能祛痘防皱纹,但并未给出功效实验数据。
公开号为CN101972241A、名称为“含有2-(3,4-二羟基苯基)乙醇或其配糖体的组合物在制备美白用组合物中的应用”的中国发明专利申请中提到一种含有野芝麻、橄榄、金桂、丁香花等植物的组合物具有提升谷胱甘肽含量和促进谷胱甘肽抗氧化的作用,从而竞争抑制黑色素的合成,实验中桂花提取物对黑色素合成抑制作用有限,在实际使用中其美白效果不显著。
发明内容
本发明要解决的技术问题之一是提供一种桂花提取物的制备方法,它工艺简单,成本低,提取的桂花提取物具有安全有效的提亮肤色作用。
为解决上述技术问题,本发明的桂花提取物的制备方法,步骤包括:
1)选取干桂花为原料,进行粉碎;
2)加入步骤1)所得原料质量的5-20倍的溶剂,在25-95℃下,搅拌提取桂花提取液30-180分钟,过滤;
3)将步骤2)所得桂花提取液离心,纯化,收集滤过液;
4)将滤过液浓缩至浸膏比重为1.10-1.30,得到桂花提取浸膏;
5)对所述桂花提取浸膏进行干燥,得到桂花提取物。
步骤2),所述溶剂为纯水或浓度不高于50%的乙醇水溶液,加入的体积优选为步骤1)所得原料体积的15倍,提取温度优选为95℃下,提取时间优选为搅拌下90min。
步骤3),可以采用陶瓷膜对离心液进行除杂纯化。陶瓷膜的较佳孔径为100-200nm。
步骤4),可以采用三效、真空薄膜或反渗透浓缩方法,浓缩条件为:温度10-80℃(优选10-60℃,更优选40℃),真空度0.04Mpa-0.09Mpa(优选0.08Mpa-0.09Mpa)。
步骤5),直接干燥或加入适宜辅料(例如麦芽糊精、倍他环糊精、阿拉伯胶、乳糖、可溶性淀粉、葡萄糖、羧甲基纤维素钠灯)后干燥。较佳的,可以采用喷雾或冻干等干燥方法,采用喷雾干燥方法时,喷雾条件为:进风温度180-200℃,出风温度80-100℃(优选90℃)。
所述桂花提取物可以是干燥的粉末、颗粒或晶体,也可以是液态的提取物或浓缩物,所述液态的提取物或浓缩物的功效量与干燥的粉末、颗粒或晶体状提取物的功效成分份量相等。
本发明要解决的技术问题之二是提供上述桂花提取物在制备亮肤与改善肤色产品中的应用。所述亮肤与改善肤色产品包括食品、药品、保健品、护理品、化妆品。
本发明通过改进桂花提取工艺,提取出具有亮肤功效的桂花提取物,与现有的桂花提取工艺及相关产品相比,本发明的桂花提取工艺和桂花提取物具有以下优点和有益效果:
1.现有的桂花提取工艺的提取溶剂中需要添加抗氧化剂,因此,在食品以及保健品领域的应用存在安全风险;而本发明仅仅使用水或低浓度乙醇作为提取溶剂,通过提取、浓缩、喷粉制备桂花提取物(所制备的桂花提取物中毛蕊花糖苷含量≥12%),完全不需要添加抗氧化剂,因此可以作为天然美白原料,安全地用于食品(可制成饮料、冲剂、糖果等形式,也可与其他食品配料、食品添加剂、浓缩果汁、果粉等复配)、药品、保健品、护理品、化妆品领域。
2.本发明的桂花提取物能够通过下调酪氨酸酶上游基因MITF,从根源上对酪氨酸酶的转录进行调控,同时抑制酪氨酸酶活性,进而抑制黑色素合成,因此,其对皮肤的提亮作用更为安全有效。
3.本发明的桂花提取工艺简单,设备投入成本低。
附图说明
图1为采用本发明的桂花提取物制备方法,在提取溶剂体积倍数和时间相同的条件下,不同提取温度下,制备得到的桂花提取物的固含量和毛蕊花糖苷含量。
图2为采用本发明的桂花提取物制备方法,在提取温度和时间相同的条件下,用不同倍数的提取溶剂(水),提取得到的桂花提取物的固含量和毛蕊花糖苷含量。
图3为采用本发明的桂花提取物制备方法,在提取溶剂体积倍数和温度相同的条件下,不同提取时间下,制备得到的桂花提取物的固含量和毛蕊花糖苷含量。
图4是本发明实施例1制备的桂花提取物对B16小鼠黑素瘤细胞内酪氨酸酶活性的影响(n=4,)。
图5是本发明实施例1制备的桂花提取物对B16小鼠黑素瘤细胞的黑色素合成的影响(n=4,)。
图6是本发明实施例1制备的桂花提取物对α-MSH(1μM)处理的B16小鼠黑素瘤细胞MITF转录因子水平的影响。
图7是本发明实施例1制备的桂花提取物对豚鼠皮肤黑色素分布部位灰度值的影响(**P<0.01vs模型对照组,n=12)。
具体实施方式
为对本发明的技术内容、特点与功效有更具体的了解,现结合附图,对本发明详述如下:
桂花提取物的制备实施例:
实施例1
干桂花粉碎后,称取2kg,加入30L水后,置于95℃水浴中搅拌提取90min,提取结束后过滤离心,过200nm陶瓷膜除杂,透过液在40℃、真空度0.08Mpa、进料速度5L/min的条件下进行真空薄膜浓缩至浸膏比重为1.30,得到桂花提取浸膏,在进风温度为180℃、出风温度为90℃条件下进行喷雾干燥,得到桂花提取粉522.8g,得率是26.14%。
实施例2
干桂花粉碎后,称取2kg,加入10L水后,置于25℃水浴中搅拌提取180min,提取结束后过滤离心,过200nm陶瓷膜除杂,透过液在60℃、真空度0.08Mpa、进料速度5L/min的条件下进行真空薄膜浓缩至浸膏比重为1.10,得到桂花提取浸膏,在进风温度为180℃、出风温度为90℃条件下进行喷雾干燥,得到桂花提取粉339.4g,得率是16.97%。
实施例3
干桂花粉碎后,称取2kg,加入40L浓度为50%的乙醇水溶液后,置于95℃水浴中搅拌提取30min,提取结束后过滤离心,过100nm陶瓷膜除杂,透过液在10℃、真空度0.09Mpa、进料速度5L/min的条件下进行真空薄膜浓缩至浸膏比重为1.20,得到桂花提取浸膏,添加90g麦芽糊精后,在进风温度为180℃、出风温度为90℃条件下进行喷雾干燥,得到桂花提取粉443.9g,得率是22.20%。
实施例4
干桂花粉碎后,称取2kg,加入10L水后,置于25℃水浴中搅拌提取180min,提取结束后过滤离心,过300nm陶瓷膜除杂,透过液在60℃、真空度0.08Mpa、进料速度5L/min的条件下进行真空薄膜浓缩至浸膏比重为1.10,得到桂花提取浸膏,在进风温度为180℃、出风温度为90℃条件下进行喷雾干燥,得到桂花提取粉312.1g,得率是15.65%。
实施例5
干桂花粉碎后,称取2kg,加入30L水后,置于95℃水浴中搅拌提取90min,提取结束后过滤离心,离心液过超滤膜,透过液在40℃、真空度0.08Mpa、进料速度5L/min的条件下进行真空薄膜浓缩至浸膏比重为1.30,得到桂花提取浸膏,在进风温度为180℃、出风温度为90℃条件下进行喷雾干燥,得到桂花提取粉273.0g,得率是13.65%。
桂花提取物的改善肤色效果实施例:
实施例6桂花提取物对B16小鼠黑素瘤细胞内酪氨酸酶活性的影响
1.细胞培养与处理
B16小鼠黑素瘤细胞(B16melanoma cell,购自上海复祥生物科技有限公司)培养在含有10%胎牛血清(上海普飞生物技术有限公司,11A2375)的DMEM高糖培养基(Corning Cellgro,R10013577)中,培养环境37℃,5%CO2。培养期间每2-3天换液一次。细胞生长至第2-4代,待其80%融合时,用0.25%的胰酶消化,并收集计数,调整细胞密度为2×104个/ml,每孔100μl加入96孔板内。经24h贴壁后,给药处理。
将实施例1-5制备的桂花提取物溶于0.01M PBS(磷酸缓冲盐溶液)中,母液浓度为0.2g/ml。
实验用含10%胎牛血清、青霉素100U/mL及链霉素100U/mL DMEM高糖培养基将B16小鼠黑素瘤细胞以2×104个/ml的密度接种于96孔板,细胞贴壁24h后给予MSH(黑色素细胞刺激素)1μM以及不同质量浓度的桂花提取物,每一质量浓度设4复孔。37℃,5%CO2条件下孵育48h后,弃上清液,并用pH7.35-7.45的0.01M PBS洗涤2次,每孔加入1%的TritonX-100溶液50μl,迅速置于-80℃冻存30min,随后室温融化使细胞完全裂解。37℃预温5min后加入1%的L-DOPA(左旋多巴)10μl,37℃反应2h,用酶标仪(全自动酶标仪,Labsystem Dragon公司生产)在490nm测定吸光度值(A490),计算细胞内酪氨酸酶活性。对照孔加入与样品量同体积的PBS。数据统计以基础值的百分比表示(%of control)。
实施例1所制备的桂花提取物对B16小鼠黑素瘤细胞内酪氨酸酶活性的试验结果如图4所示。由图4可知,给予MSH可增强B16细胞酪氨酸酶的活性,这种作用可被桂花提取物所抑制(0.125-0.5mg/ml)。B16小鼠黑素瘤细胞中酪氨酸酶活性随着桂花提取物浓度的升高而降低。桂花提取物0.5mg/ml组的酪氨酸酶活性为MSH组的48.53%,对酪氨酸酶活性的抑制效果优于公开号为CN103767975A的发明专利申请中的实施例3(0.850mg/ml)。
测试实施例1-2产品在剂量0.5mg/ml、实施例3产品在剂量0.63mg/ml(折算剂量)和实施例4-5产品在剂量0.5mg/ml下的B16细胞酪氨酸酶活性,并与MSH组比较作为结果列于表1:
表1实施例1-5产品的B16细胞酪氨酸酶活性对比
实施例7桂花提取物对B16小鼠黑素瘤细胞中黑素含量的影响
实验用含10%胎牛血清、青霉素100U/mL及链霉素100U/mL DMEM高糖培养基将B16小鼠黑素瘤细胞密度调为1×105个/mL,以每孔3mL接种于6孔细胞培养板中,在37℃、5%CO2条件下培养24h后,给予MSH 1μM以及不同浓度的实施例1的桂花提取物,共培养48h。弃上清并用PBS洗涤,PBS清洗后用0.25%的胰酶消化细胞,离心并收集细胞,加入200μl含有10%DMSO(二甲亚砜)的1mol/L NaOH裂解细胞,80℃条件下孵育2h,用酶标仪在490nm波长下测定吸光度值(A490),计算黑色素合成率。其中,对照孔加入与样品量同体积的PBS。B16细胞的蛋白浓度以BCA法测定,用于吸光度的校正。数据统计以基础值的百分比表示(%ofcontrol)。
待测样品对B16小鼠黑素瘤细胞的黑色素合成的影响结果如图5所示。
根据实施例6中桂花提取物的作用,选择0.125-0.5mg/ml剂量进一步观察其对黑素水平的影响。桂花提取物在0.125-0.5mg/ml剂量范围内可抑制由MSH(1μM)诱发的B16黑素水平的增高,并且抑制效果随着桂花提取物浓度的增加而增加。
测试实施例1-2的产品在剂量0.5mg/ml、实施例3的产品在剂量0.63mg/ml(折算剂量)和实施例4、5产品在剂量0.5mg/ml下的B16小鼠黑素瘤细胞的黑色素水平的影响,并与MSH组比较作为结果列于表2:
表2实施例1-5对B16小鼠黑素瘤细胞中黑色素水平的影响对比
实施例8桂花提取物对B16小鼠黑素瘤细胞内MITF转录因子的作用
采用Western blotting对黑素合成相关的转录因子MITF进行分析。B16细胞以1×105个/ml的密度接种于6孔板,贴壁24h后给予MSH(Sigma,014M4822V)(1μM)以及不同浓度的受试物共培养48h。PBS清洗后各孔加入250μl冰冷的RIPA裂解液(内含蛋白酶抑制剂,PMSF(苯甲基磺酰氟)100μM,Aprotinin(抑肽酶)和Leupepsin(亮抑蛋白酶肽)10μg/ml),并在12000rpm条件下离心25min(4℃),收集上清并以BCA法测定蛋白浓度。蛋白以12%SDS-PAGE(十二烷基磺酸钠-聚丙烯酰胺凝胶电泳)分离,并转移至PVDF(聚偏氟乙烯)膜上。膜先以含有10%脱脂奶粉的TBST封闭,然后与兔抗小鼠MITF(Santa Cruz Biotechnology,L4894)4℃条件下孵育过夜,TBST漂洗3遍,每遍5min,然后与带有HRP(辣根过氧化物酶)的羊抗兔二抗(Santa Cruz Biotechnology,sc-2004)室温条件下反应1h,ECL(增强化学发光法,Millipore,Billerica,MA,USA)反应1min,并用FluorChem E成像系统拍照(ProteinSimple,Santa Clara,CA,USA)。beta-Actin作为内参。
由图6可知,MSH使B16小鼠黑素瘤细胞中MITF转录因子显著上调,桂花提取物能够抑制MITF上调,随着浓度上升这种抑制作用逐渐增强。
实施例9动物实验——豚鼠UVB紫外线照射诱导皮肤黑色素沉着模型
1.实验动物:
花色豚鼠,购自上海甲干生物科技有限公司,生产许可证号:SCXK(沪)2010-0028,使用许可证号:SYXK(沪)2013-0087。
将60只健康雌性豚鼠适应性饲养一周,按体重分层后随机分成5组,每组12只,同组动物均在同一笼进行饲养。
2.仪器:
UVB紫外辐照计,型号SH-4B,购自上海希格玛高技术有限公司。
色差仪,型号NH310,购自深圳市三恩驰科技有限公司。
3.实验过程:
各组剂量折算方法:人体食用量为50ml/日,则人体的剂量为0.83ml/kg(按照60kg)计算,折算到豚鼠为3.75ml/kg(折算系数为4.5),将受试物统一按照灌胃剂量5ml/kg进行稀释后,灌胃。
各试验组均于每天上午9到11点给予受试样品,所有受试物均采取口服灌胃方式给予,模型组给予等容积的溶剂。连续给药30天,给药体积为5ml/kg,给药浓度为1.5-6mg/ml。每5天称取体重一次,并根据体重调整给药量。实验分为:模型组(n=12),VC对照组(300mg/kg,n=12),实施例1的桂花提取物高剂量组(30mg/kg,n=12)、实施例1的桂花提取物中剂量组(15mg/kg,n=12)、实施例1的桂花提取物低剂量组(7.5mg/kg,n=12)、实施例2的桂花提取物高剂量组(30mg/kg,n=12)、实施例3的桂花提取物高剂量组(30mg/kg,n=12)、实施例4的桂花提取物高剂量组(30mg/kg,n=12)、实施例5的桂花提取物高剂量组(30mg/kg,n=12)。
受试物连续给予30天,UVB照射时间为在给予受试物后的第3、5、7、9天进行。照射剂量为200mJ/cm2,总共照射4次,总剂量800mJ/cm2。照射前所有豚鼠于背部棕色部位剃毛备用,剃毛面积4cm×4cm。
实验结束时,取照射部位皮肤固定,进行Fontana Masson染色。病理染色黑色素分布部位灰度值采用单因素方差分析,组间比较采用student Newman-Keuls分析检验,以P<0.05为差异比较具有统计学意义,结果列于表3:
表3不同实验组豚鼠皮肤病理染色黑色素分布部位灰度值对比
4.结果:
桂花提取物对豚鼠皮肤病理染色黑色素分布部位灰度值的影响如图7所示。由图7可知,桂花提取物(高、中、低)剂量组Fontana Masson染色黑色素分布部位的灰度值均显著低于模型对照组(P<0.01),具有一定的量效关系,并且中、高剂量组的改善肤色效果优于阳性对照VC组。
Claims (10)
1.桂花提取物的制备方法,其特征在于,步骤包括:
1)选取干桂花为原料,进行粉碎;
2)加入步骤1)所得原料质量的5-20倍的溶剂,在25-95℃下,搅拌提取桂花提取液30-180分钟,过滤;
3)将步骤2)所得桂花提取液离心,纯化,收集滤过液;
4)将滤过液浓缩至浸膏比重为1.10-1.30,得到桂花提取浸膏;
5)对所述桂花提取浸膏进行干燥,得到桂花提取物。
2.根据权利要求1所述的方法,其特征在于,所述桂花提取物为干燥的粉末、颗粒或晶体,或液态的提取物或浓缩物,所述液态的提取物或浓缩物的功效量与干燥的粉末、颗粒或晶体状提取物的功效成分份量相等。
3.根据权利要求1所述的方法,其特征在于,步骤2),所述溶剂为水或浓度不高于50%的乙醇水溶液,加入的体积为步骤1)所得原料体积的15倍,提取温度为95℃,提取时间为90min。
4.根据权利要求1所述的方法,其特征在于,步骤3),采用陶瓷膜对离心液进行除杂纯化,所述陶瓷膜的孔径为100-200nm。
5.根据权利要求1所述的方法,其特征在于,步骤4),采用三效、真空薄膜或反渗透浓缩方法,浓缩条件为:温度10-80℃,真空度0.04Mpa-0.09Mpa。
6.根据权利要求5所述的方法,其特征在于,步骤4),浓缩条件为:温度10-60℃,真空度0.08Mpa-0.09Mpa。
7.根据权利要求6所述的方法,其特征在于,步骤4),浓缩温度为40-60℃。
8.根据权利要求1所述的方法,其特征在于,步骤5),采用直接干燥或加入辅料后干燥。
9.权利要求1所述桂花提取物在制备提亮肤色产品中的应用。
10.根据权利要求9所述的应用,其特征在于,所述提亮肤色产品包括食品、药品、保健品、护理品、化妆品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610255932.XA CN105832603A (zh) | 2016-04-22 | 2016-04-22 | 桂花提取物的制备方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610255932.XA CN105832603A (zh) | 2016-04-22 | 2016-04-22 | 桂花提取物的制备方法及应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105832603A true CN105832603A (zh) | 2016-08-10 |
Family
ID=56589958
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610255932.XA Pending CN105832603A (zh) | 2016-04-22 | 2016-04-22 | 桂花提取物的制备方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105832603A (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106381223A (zh) * | 2016-10-31 | 2017-02-08 | 湖北中烟工业有限责任公司 | 一种用于卷烟纸的桂花香精 |
CN106819918A (zh) * | 2016-12-30 | 2017-06-13 | 安徽省麦浪食品有限公司 | 一种红烧桂花鸽 |
CN112970839A (zh) * | 2019-12-13 | 2021-06-18 | 盐津铺子食品股份有限公司 | 一种干果挂膜用变性淀粉及其制备方法 |
CN113398030A (zh) * | 2021-07-09 | 2021-09-17 | 广州集妍化妆品科技有限公司 | 桂花提取物及其制备方法和化妆品 |
CN116159089A (zh) * | 2023-01-10 | 2023-05-26 | 浙江大学 | 一种苯乙醇苷提取物及其制备方法和在抗糖化中的应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103223018A (zh) * | 2013-05-08 | 2013-07-31 | 浙江大学 | 桂花多酚提取物及其制备方法和用途 |
CN103768152A (zh) * | 2014-01-29 | 2014-05-07 | 浙江大学 | 桂花苯乙醇苷提取物及其制备方法和用途 |
CN103767975A (zh) * | 2014-01-29 | 2014-05-07 | 浙江大学 | 桂花苯乙醇苷提取物在制备美白化妆品中的应用 |
CN104758303A (zh) * | 2014-01-08 | 2015-07-08 | 昆明制药集团股份有限公司 | 曲札茋苷在制备治疗肺损伤或急性呼吸窘迫综合征的药物的用途 |
CN104886593A (zh) * | 2015-06-02 | 2015-09-09 | 无限极(中国)有限公司 | 具有美白作用的组合物及其应用 |
-
2016
- 2016-04-22 CN CN201610255932.XA patent/CN105832603A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103223018A (zh) * | 2013-05-08 | 2013-07-31 | 浙江大学 | 桂花多酚提取物及其制备方法和用途 |
CN104758303A (zh) * | 2014-01-08 | 2015-07-08 | 昆明制药集团股份有限公司 | 曲札茋苷在制备治疗肺损伤或急性呼吸窘迫综合征的药物的用途 |
CN103768152A (zh) * | 2014-01-29 | 2014-05-07 | 浙江大学 | 桂花苯乙醇苷提取物及其制备方法和用途 |
CN103767975A (zh) * | 2014-01-29 | 2014-05-07 | 浙江大学 | 桂花苯乙醇苷提取物在制备美白化妆品中的应用 |
CN104886593A (zh) * | 2015-06-02 | 2015-09-09 | 无限极(中国)有限公司 | 具有美白作用的组合物及其应用 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106381223A (zh) * | 2016-10-31 | 2017-02-08 | 湖北中烟工业有限责任公司 | 一种用于卷烟纸的桂花香精 |
CN106819918A (zh) * | 2016-12-30 | 2017-06-13 | 安徽省麦浪食品有限公司 | 一种红烧桂花鸽 |
CN112970839A (zh) * | 2019-12-13 | 2021-06-18 | 盐津铺子食品股份有限公司 | 一种干果挂膜用变性淀粉及其制备方法 |
CN113398030A (zh) * | 2021-07-09 | 2021-09-17 | 广州集妍化妆品科技有限公司 | 桂花提取物及其制备方法和化妆品 |
CN116159089A (zh) * | 2023-01-10 | 2023-05-26 | 浙江大学 | 一种苯乙醇苷提取物及其制备方法和在抗糖化中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101041403B1 (ko) | 항산화 및 미백용 화장료 조성물 | |
KR101194059B1 (ko) | 한방 생약재 추출물을 포함하는 탈모방지 및 발모용 세정제 조성물 및 이의 제조방법 | |
CN105832603A (zh) | 桂花提取物的制备方法及应用 | |
KR20210038369A (ko) | 한방생물 추출물을 포함하는 탈모방지 및 발모용 세정제 조성물 및 이의 제조방법 | |
JP5137457B2 (ja) | 幹細胞増殖因子発現上昇抑制剤 | |
CN104784507A (zh) | 一种具有多重美容功效的中药组合物及其制备方法和应用 | |
KR20180110939A (ko) | 식물 추출물을 유효성분으로 포함하는 탈모 방지 및 발모 촉진용 조성물 | |
CN106214592A (zh) | 毛囊营养液组合物及其制备方法 | |
CN105288246A (zh) | 一种美白抗皱中药组合物及其混合提取物和应用 | |
KR101787531B1 (ko) | 생약 복합 추출물을 함유하는 탈모 방지용 조성물 | |
KR102009676B1 (ko) | 대나무 발효물을 함유하는 화장료 조성물 | |
CN113304093A (zh) | 一种具有美白护肤功效的化妆品原料组合物的制备方法及含有原料组合物的化妆品 | |
CN109481344B (zh) | 一种植物多糖组合物及其应用 | |
KR100760670B1 (ko) | 미백효과를 갖는 천연팩용 조성물의 제조방법 | |
CN103126970B (zh) | 用于防脱发或促进毛发生长的组合物 | |
KR102094846B1 (ko) | 피부 개선에 효능이 있는 혼합생약 화장료 조성물의 제조방법 및 이를 통해 제조된 혼합생약 화장료 조성물 | |
JP6527715B2 (ja) | 黒生姜含有組成物 | |
CN103540496B (zh) | 一种中药养生保健酒及其制备方法 | |
KR101990387B1 (ko) | 황련 추출물을 포함하는 한방 화장료 조성물 | |
KR20170137549A (ko) | 복합 생약 추출물을 포함하는 피부 개선용 조성물 | |
KR101754376B1 (ko) | 두피에의 영양분 공급, 흡수 및 이용에 효과적인 백모 개선용 조성물 | |
CN113631227B (zh) | 抗老化剂、抗氧化剂、抗炎剂、及美白剂、以及化妆品 | |
EP3041586A1 (en) | Skin care composition | |
CN105168065B (zh) | 一种多效美白祛斑精华霜及其制备方法 | |
KR102124556B1 (ko) | 청보리 추출물을 포함하는 피부 미백 화장품 및 이의 제조 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160810 |
|
RJ01 | Rejection of invention patent application after publication |